Skip to content

Enhancement of one exposure session for social anxiety disorder with transcranial alternating current stimulation: a proof-of-concept study

Enhancement of one exposure session for social anxiety disorder with transcranial alternating current stimulation: a proof-of-concept study - Exposure enhancement with tACS in SAD

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON56518
Enrollment
60
Registered
2023-09-19
Start date
2024-09-26
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

performance anxiety, social anxiety disorder, social phobia, speech anxiety social anxiety

Interventions

Participants will receive brief standardized exposure consisting of two exposure sessions one week apart in which participants give a speech in front of an audience and a video camera. The first expos

Sponsors

Radboud Universiteit Nijmegen
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: A. 18-45 years old B. Meeting the DSM-5 criteria for SAD as assessed with the Mini International Neuropsychiatric Interview (MINI), with a predominant fear of public speaking C. Self-reported SAD symptoms above clinical cut-off (score > 30 on the Liebowitz Social Anxiety Scale) D. Magnetic resonance imaging (MRI) compatible E. tACS compatible

Exclusion criteria

Exclusion criteria: A. Prior non-response to exposure therapy (i.c. speech exposure) for SAD  symptoms, as defined by the subject's report of receiving specific and regular  exposure assignments as part of previous therapy B. Entry of subjects with other mood or anxiety disorders will be permitted in  order to increase accrual of a clinically relevant sample; however, in cases  where SAD is not judged to be the predominant disorder, participants will not  be eligible C. Psychosis or delusion disorders (current or in the past)  D. Subjects with significant suicide ideations or who have enacted suicidal  behaviors within 6 months prior to intake will be excluded from participation  and referred for appropriate clinical intervention E. Intellectual disability  F. Substance or alcohol dependence  G. Somatic illness H. Pregnancy or lactation I. Antipsychotic medication  J. Participants that use antidepressants or benzodiazepines will not be  excluded, but have to be on a stable dose for at least 6 weeks prior to  enrollment K. Insufficient ability to speak and write DutchL. Subjects who are far- or near-sighted outside of the -3 to +3 optometric range can only participate if they wear contact lenses during Day 2 and Day 3

Design outcomes

Primary

MeasureTime frame
The main outcome of the study is subjective anxiety during the speech delivery as assessed with subjective units of distress ratings.

Secondary

MeasureTime frame
Additional parameters are self-reported social anxiety symptoms (via the Social Phobia Scale questionnaire), in-session avoidance behaviour (body posture, speech prosody, eye gaze), magnetic resonance imaging scans, physiological measures (heart rate, skin conductance, salivary testosterone and cortisol), implicit measures of approach-avoidance biases to emotional faces (via the computerized Approach-Avoidance Task), and computational estimates of learning rate adaptation to volatility (via the computerized Reversal Learning Task).

Countries

Netherlands

Contacts

Public ContactM Carneiro de Andrade

Radboud Universiteit Nijmegen

mariana.carneirodeandrade@ru.nl+31 6 57724553

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)